Bifogade filer
Kurs
-1,18%
Likviditet
12,8 MSEK
Kalender
Est. tid* | ||
2025-11-06 | 07:00 | Kvartalsrapport 2025-Q3 |
2025-07-17 | 07:00 | Kvartalsrapport 2025-Q2 |
2025-05-28 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
2025-05-27 | - | Årsstämma |
2025-05-15 | - | Kvartalsrapport 2025-Q1 |
2025-02-13 | - | Bokslutskommuniké 2024 |
2024-11-07 | - | Kvartalsrapport 2024-Q3 |
2024-07-16 | - | Kvartalsrapport 2024-Q2 |
2024-05-10 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
2024-05-08 | - | Årsstämma |
2024-05-08 | - | Kvartalsrapport 2024-Q1 |
2024-02-15 | - | Bokslutskommuniké 2023 |
2023-11-09 | - | Kvartalsrapport 2023-Q3 |
2023-07-18 | - | Kvartalsrapport 2023-Q2 |
2023-05-11 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
2023-05-10 | - | Årsstämma |
2023-05-10 | - | Kvartalsrapport 2023-Q1 |
2023-02-14 | - | Bokslutskommuniké 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-07-15 | - | Kvartalsrapport 2022-Q2 |
2022-05-13 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
2022-05-12 | - | Årsstämma |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-02-16 | - | Bokslutskommuniké 2021 |
2021-11-04 | - | Kvartalsrapport 2021-Q3 |
2021-07-15 | - | Kvartalsrapport 2021-Q2 |
2021-05-07 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
2021-05-06 | - | Årsstämma |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-02-11 | - | Bokslutskommuniké 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-07-16 | - | Kvartalsrapport 2020-Q2 |
2020-05-08 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
2020-05-07 | - | Årsstämma |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-02-12 | - | Bokslutskommuniké 2019 |
2019-11-08 | - | Kvartalsrapport 2019-Q3 |
2019-07-18 | - | Kvartalsrapport 2019-Q2 |
2019-05-10 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
2019-05-09 | - | Årsstämma |
2019-05-09 | - | Kvartalsrapport 2019-Q1 |
2019-02-06 | - | Bokslutskommuniké 2018 |
2018-10-25 | - | Kvartalsrapport 2018-Q3 |
2018-07-17 | - | Kvartalsrapport 2018-Q2 |
2018-05-04 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
2018-05-03 | - | Årsstämma |
2018-05-03 | - | Kvartalsrapport 2018-Q1 |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-10-26 | - | Kvartalsrapport 2017-Q3 |
2017-07-13 | - | Kvartalsrapport 2017-Q2 |
2017-05-04 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
2017-05-03 | - | Årsstämma |
2017-05-03 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-10-22 | - | Kvartalsrapport 2016-Q3 |
2016-07-14 | - | Kvartalsrapport 2016-Q2 |
2016-05-17 | - | Kvartalsrapport 2016-Q1 |
2016-05-04 | - | X-dag ordinarie utdelning CAMX 0.00 SEK |
2016-05-03 | - | Årsstämma |
2016-03-30 | - | Bokslutskommuniké 2015 |
Beskrivning
Land | Sverige |
---|---|
Lista | Large Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Lund, Sweden - 4 January 2021 - Camurus AB (NASDAQ STO: CAMX) today announces the appointment of Andrew McLean to the position of Vice President, Corporate Development and Senior Counsel, and a member of Camurus' Management Team.
Andrew McLean brings more than 25 years of experience from work with corporate development, licensing, merger & acquisitions, and compliance in the international pharmaceutical industry. Most recently, he was General Counsel, Company Secretary & Chief Compliance Officer at Kyowa Kirin International Plc (formerly ProStrakan). Prior to this he held senior positions at Recordati and Shire Pharmaceuticals.
Andrew McLean succeeds Urban Paulsson, who leaves his current Management Team position for other engagements and will continue to serve Camurus as a consultant.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal[®] drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit camurus.com (http://www.camurus.com).
The information was submitted for publication at 8:00 am CET on 4 January 2021.